Trial Profile
Pretargeted Radioimmunotherapy of Colorectal Cancer: A Phase I Study to Determine Dose-limiting Toxicity and Maximum Tolerated Dose of an Anti-CEACAM5 bsMAb-pretargeted 90Y-hapten-peptide.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs IMP 288 (Primary) ; TF 2 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 03 Dec 2020 Status has been changed to withdrawn prior to enrolment.
- 24 Sep 2012 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Jan 2011 New trial record